Showing 171-180 of 1310 results for "".
- Business News: Solta IPO Put on Icehttps://practicaldermatology.com/news/business-news-solta-ipo-put-on-ice/2461239/Bausch Health Companies Inc. is suspending its plans for the Solta IPO due to challenging market conditions and other factors. Bausch Health stated that the interests of the Company's stakeholders are best served in the near-term by focusing on driving Solta's revenue, profits a
- Crown to Acquire Aesthetic Product Portfolio from Eclipsehttps://practicaldermatology.com/news/crown-to-acquire-aesthetic-product-portfolio-from-eclipse/2461208/Crown Laboratories will acquire the global aesthetics-focused assets of Eclipse. The acquisition expands Crown's aesthetics' product portfolio and enhances Crown's overall value proposition as a global leader in science-based aesthetic skincare solutions. "We
- CHMP Recommends Approval of Lilly and Incyte's Olumiant for Severe AAhttps://practicaldermatology.com/news/chmp-recommends-approval-of-lilly-and-incytes-olumiant-for-severe-aa/2461204/The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Eli Lilly and Company and Incyte’s Olumiant (baricitinib) for the treatment of adults with severe alopecia areata (AA). This opinion marks the fir
- FDA Issues Complete Response Letter for UCB's Bimekizumabhttps://practicaldermatology.com/news/fda-issues-complete-response-letter-for-ucbs-bimekizumab/2461195/There’s a delay in the US regulatory review of UCB’s bimekizumab for the treatment of adults with moderate to severe plaque psoriasis. FDA has indicated it cannot approve the BLA for bimekizumab in its current form. The agency issued a Complete Response Letter (CRL) that sta
- TOOsonix System ONE-M BCC Clinical Trial Updatehttps://practicaldermatology.com/news/toosonix-system-one-m-bcc-clinical-trial-update/2461162/The first basal cell carcinoma (BCC) patients have been treated with TOOsonix A/S’s System ONE-M device. The TOOsonix high-intensity focused ultrasound (HIFU) delivers highly accurate doses of energy to focal points in a chosen depth. It operates at 20 MHz to
- Bill Scott Named President of Endymed's US Subsidiaryhttps://practicaldermatology.com/news/bill-scott-named-president-of-endymeds-us-subsidiary/2461151/Bill Scott is the new president of Endymed Ltd’s US subsidiary, Endymed Inc. Mr. Scott will be responsible for leading Endymed's sales teams in the United States. The Company believes that the joining of Mr. Scott will drive its US growth plan and help secure a signi
- Alma Launches Alma TED, CBD+ Professional Linehttps://practicaldermatology.com/news/alma-launches-alma-ted-cbd-professional-line/2461132/Alma TED, an Ultrasound-based system with a propriety Tip engineered with Impact Delivery™, offers a non-invasive, non-traumatic option to address the market's growing hair loss concerns. Alma launched the device, along with the CBD+ Professional S
- Study: Use of DermTech’s Melanoma Test Can Cut Costshttps://practicaldermatology.com/news/study-use-of-dermtechs-melanoma-test-can-cut-costs/2461102/New research shows that DermTech’s Pigmented Lesion Assay can reduce costs for commercial health insurance plans when it’s incorporated into the current care pathway of assessing pigmented skin lesions or moles suspicious for melanoma The
- Solta Medical Files for IPOhttps://practicaldermatology.com/news/solta-medical-files-for-ipo/2461072/Bausch Subsidiary Solta Medical Corporation is getting ready to go public. The Company publicly filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering ("IPO") of Solta's common shares.
- Avita Medical's Spray-On Skin Cells Demonstrate Proof of Concept in Aging Skin and EBhttps://practicaldermatology.com/news/avita-medicals-spray-on-skin-cells-demonstrate-proof-of-concept-in-rejuvenation-and-eb/2461028/Preclinical data successfully established proof of concept for Avita Medical’s Spray-On Skin Cells in skin rejuvenation and epidermolysis bullosa (EB), the company reports. AVITA Medical’s first US product, the RECELL System, was approved by FDA in September 2018.